Neuroprogression: the hidden mechanism of depression
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
For many years, depressive disorder (DD) was considered a transient and natural disease of people's mood. Its etiology had been attributed mainly to biochemical alterations of the monoamines and their receptors. Nevertheless, its prevalence and considerable impact on the family and social environment of those afflicted by it have placed the disease as a global public health problem. Neuroprogression is the term used to describe the changes in several psychiatric conditions evidenced and observed in the clinical manifestations, biochemical markers, and cerebral structures of the patients with major depressive disorder (MDD), which frequently overlap with neurodegenerative disorders. DD is considered a potentially aggressive state of neuronal deterioration involving apoptosis, reduced neurogenesis, decreased neuronal plasticity, and increased immune response. Clinically, it encompasses a poor response to treatment and an increase in depressive episodes, both of which bring about vulnerability and decline of functions associated with structural changes in the brain. The interest of this work is to review the metabolic processes involved in the morphologic alterations in the limbic system reported in patients with MDD, as well as the neurologic bases of this complex pathology that include environmental stress, genetic vulnerability, alterations in the neurotransmission, and changes in the neuroplasticity, all of which today bring into limelight a mechanism of progressive neuronal damage.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
From inflammation to sickness and depression: when the immune system subjugates the brain
Dantzer, R., O'Connor, J. C., Freund, G. G., Johnson, R. W., & Kelley, K. W. (2008) · Nature Reviews Neuroscience · doi:10.1038/nrn2297 · Cited by 7,395
Protein aggregation and neurodegenerative disease
Ross, C. A., & Poirier, M. A. (2004) · Nature Medicine · doi:10.1038/nm1066 · Cited by 3,454 · cited 1×
“62 expectatives Currently, MDD is recognized as an accelerated and aggressive, neurotoxic, and neurodegenerative process that incapacitates the patient.”
BackgroundA Neurotrophic Model for Stress-Related Mood Disorders
Duman, R. S., & Monteggia, L. M. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.02.013 · Cited by 3,375
Drevets, W. C., Price, J. L., & Furey, M. L. (2008) · Brain Structure and Function · doi:10.1007/s00429-008-0189-x · Cited by 2,241 · cited 1×
“11 The findings reported indicate that, different from other pathologies such as Parkinson’s and Huntington’s diseases where the alterations are located in a specific region of the brain, DD involves a complex set of structures that form the highly organized circuits involved in the control of…”
BackgroundDong, X.-X., Wang, Y., & Qin, Z.-H. (2009) · Acta Pharmacologica Sinica · doi:10.1038/aps.2009.24 · Cited by 1,297
Berk, M., Kapczinski, F., Andreazza, A. C., Dean, O. M., Giorlando, F., Maes, M., Yücel, M., Gama, C. S., Dodd, S., Dean, B., et al. (2011) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2010.10.001 · Cited by 1,178
Maes, M., Galecki, P., Chang, Y. S., & Berk, M. (2011) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.05.004 · Cited by 1,140
The macrophage theory of depression
Smith, R. S. (1991) · Medical Hypotheses · doi:10.1016/0306-9877(91)90272-z · Cited by 931 · cited 1×
“The participation of proinflammatory cytokines in DD was proposed by Smith 63 in his “macrophage theory of depression” and later studied by Maes 64 in the beginning of the 1990s.”
BackgroundLamers, F., Vogelzangs, N., Merikangas, K. R., de Jonge, P., Beekman, A. T. F., & Penninx, B. W. J. H. (2013) · Molecular Psychiatry · doi:10.1038/mp.2012.144 · Cited by 691
Moylan, S., Maes, M., Wray, N. R., & Berk, M. (2013) · Molecular Psychiatry · doi:10.1038/mp.2012.33 · Cited by 529
Overview of the Genetics of Major Depressive Disorder
Lohoff, F. W. (2010) · Current Psychiatry Reports · doi:10.1007/s11920-010-0150-6 · Cited by 498 · cited 1×
“27 The non-Mendelian genetic predisposition found in the allelic variants of some patients is related to the synthesis and expression of genes encoding proteins involved in the synthesis of tyrosine hydroxylase enzyme that limits DA synthesis.”
BackgroundImmune mechanisms linked to depression via oxidative stress and neuroprogression
Bakunina, N., Pariante, C. M., & Zunszain, P. A. (2015) · Immunology · doi:10.1111/imm.12443 · Cited by 444 · cited 1×
“37,38 In depression, the reduction in the size of frontal lobes, prefrontal orbital cortex, circumvolution of the frontal corpus callosum, hippocampus, and amygdala seems to reflect a decrease of neurogenesis, mitochondrial dysfunction, and an imbalance in HHS axis in depressed patients.”
BackgroundRajMohan, V, & Mohandas, E. (2007) · Indian Journal of Psychiatry · doi:10.4103/0019-5545.33264 · Cited by 342
Markers of Oxidative Stress and Neuroprogression in Depression Disorder
Vaváková, M., Ďuračková, Z., & Trebatická, J. (2015) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2015/898393 · Cited by 324 · cited 2×
“57 Given the damage generated by OS, astrocytes try to attenuate the inflammatory and apoptotic response through various neuroprotection pathways.”
BackgroundMorphological Brain Changes in Depression: Can Antidepressants Reverse Them?
Miguel-Hidalgo, J. J., & Rajkowska, G. (2002) · CNS Drugs · doi:10.2165/00023210-200216060-00001 · Cited by 64
Cited by
Tartt, A. N., Mariani, M. B., Hen, R., Mann, J. J., & Boldrini, M. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01520-y · Cited by 408
“Neuroplasticity is defined as the brain’s ability to undergo neurobiological changes in response to extrinsic stimuli such as early life adversity [5–7] and chronic exposure to stress [8, 9] and/ or intrinsic stimuli most notably genetic or epigenetic effects [10, 11].”
BackgroundBerk, M., Köhler‐Forsberg, O., Turner, M., Penninx, B. W. J. H., Wrobel, A., Firth, J., Loughman, A., Reavley, N. J., McGrath, J. J., Momen, N. C., et al. (2023) · World Psychiatry · doi:10.1002/wps.21110 · Cited by 336
Repurposing of the β-Lactam Antibiotic, Ceftriaxone for Neurological Disorders: A Review
Yimer, E. M., Hishe, H. Z., & Tuem, K. B. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00236 · Cited by 72
Serafini, G., Pardini, M., Monacelli, F., Orso, B., Girtler, N., Brugnolo, A., Amore, M., Nobili, F., & Team on Dementia of the IRCCS Ospedale Policlinico San Martino (2021) · Brain Sciences · doi:10.3390/brainsci11020276 · Cited by 56
“, atrophy and volume loss, as well as cognitive decline and vulnerability to psychological stress) and their association with a more severe course of illness [4,5].”
BackgroundmGluR5 Facilitates Long-Term Synaptic Depression in a Stress-Induced Depressive Mouse Model
Jiang, X., Lin, W., Cheng, Y., & Wang, D. (2020) · The Canadian Journal of Psychiatry · doi:10.1177/0706743719874162 · Cited by 18
“There are two types of synaptic plasticity: LTD and long-term potentiation (LTP) featured by long-lasting decreased or increased synaptic strength.15 Previous evidence has shown that in the depression rodent models, LTD is the major change in synaptic plasticity without obvious change in LTP.28 Consistent with previou…”
Result
Metadata
- Authors
- Labra Ruiz, N. A., Santamaría del Ángel, D., Juárez Olguín, H., & Lindoro Silva, M.
- Venue
- Neuropsychiatric Disease and Treatment
- Publisher
- Informa UK Limited
- Published
- 2018-10
- Volume
- Volume 14
- Pages
- 2837-2845
- ISSN
- 1176-6328 (ISSN-L)
- 1178-2021
- OpenAlex
- W2898691989
- Cited by
- 73
- References
- 15
- FWCI
- 3.11
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.